Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free DRMAW Stock Alerts

Dermata Therapeutics (DRMAW) Competitors

Dermata Therapeutics logo
$0.0006 0.00 (0.00%)
As of 08/17/2026
This is a fair market value price provided by Massive. Learn more.
Compare

DRMAW vs. DSYWW, PRENW, WALDW, PG, and UL

Should you buy Dermata Therapeutics stock or one of its competitors? Dermata Therapeutics's main competitors and comparable companies include Big Tree Cloud (DSYWW), Prenetics Global (PRENW), Waldencast (WALDW), Procter & Gamble (PG), and Unilever (UL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Dermata Therapeutics compare to Big Tree Cloud?

Big Tree Cloud (NASDAQ:DSYWW) and Dermata Therapeutics (NASDAQ:DRMAW) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Company Net Margins Return on Equity Return on Assets
Big Tree CloudN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Big Tree Cloud$2.02MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Big Tree Cloud had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 1 mentions for Big Tree Cloud and 0 mentions for Dermata Therapeutics. Big Tree Cloud's average media sentiment score of 1.89 beat Dermata Therapeutics' score of 0.00 indicating that Big Tree Cloud is being referred to more favorably in the media.

Company Overall Sentiment
Big Tree Cloud Very Positive
Dermata Therapeutics Neutral

Summary

Big Tree Cloud beats Dermata Therapeutics on 3 of the 3 factors compared between the two stocks.

How does Dermata Therapeutics compare to Prenetics Global?

Dermata Therapeutics (NASDAQ:DRMAW) and Prenetics Global (NASDAQ:PRENW) are both consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

In the previous week, Prenetics Global had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 1 mentions for Prenetics Global and 0 mentions for Dermata Therapeutics. Prenetics Global's average media sentiment score of 1.87 beat Dermata Therapeutics' score of 0.00 indicating that Prenetics Global is being referred to more favorably in the news media.

Company Overall Sentiment
Dermata Therapeutics Neutral
Prenetics Global Very Positive

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Prenetics Global N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Prenetics Global$154.59MN/AN/AN/AN/A

Summary

Prenetics Global beats Dermata Therapeutics on 3 of the 3 factors compared between the two stocks.

How does Dermata Therapeutics compare to Waldencast?

Dermata Therapeutics (NASDAQ:DRMAW) and Waldencast (NASDAQ:WALDW) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Waldencast N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Waldencast$272.07MN/AN/AN/AN/A

In the previous week, Waldencast had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 1 mentions for Waldencast and 0 mentions for Dermata Therapeutics. Waldencast's average media sentiment score of 1.89 beat Dermata Therapeutics' score of 0.00 indicating that Waldencast is being referred to more favorably in the news media.

Company Overall Sentiment
Dermata Therapeutics Neutral
Waldencast Very Positive

Summary

Waldencast beats Dermata Therapeutics on 3 of the 3 factors compared between the two stocks.

How does Dermata Therapeutics compare to Procter & Gamble?

Dermata Therapeutics (NASDAQ:DRMAW) and Procter & Gamble (NYSE:PG) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Procter & Gamble had 37 more articles in the media than Dermata Therapeutics. MarketBeat recorded 37 mentions for Procter & Gamble and 0 mentions for Dermata Therapeutics. Procter & Gamble's average media sentiment score of 0.90 beat Dermata Therapeutics' score of 0.00 indicating that Procter & Gamble is being referred to more favorably in the news media.

Company Overall Sentiment
Dermata Therapeutics Neutral
Procter & Gamble Positive

Procter & Gamble has a consensus price target of $161.19, indicating a potential upside of 11.07%. Given Procter & Gamble's stronger consensus rating and higher probable upside, analysts plainly believe Procter & Gamble is more favorable than Dermata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermata Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Procter & Gamble
0 Sell rating(s)
11 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.54

Procter & Gamble has a net margin of 18.44% compared to Dermata Therapeutics' net margin of 0.00%. Procter & Gamble's return on equity of 31.36% beat Dermata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Procter & Gamble 18.44%31.36%13.09%

Procter & Gamble has higher revenue and earnings than Dermata Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Procter & Gamble$87.03B3.87$16.05B$6.6221.92

65.8% of Procter & Gamble shares are held by institutional investors. 0.2% of Procter & Gamble shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Procter & Gamble beats Dermata Therapeutics on 11 of the 11 factors compared between the two stocks.

How does Dermata Therapeutics compare to Unilever?

Dermata Therapeutics (NASDAQ:DRMAW) and Unilever (NYSE:UL) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Unilever N/A N/A N/A

Unilever has higher revenue and earnings than Dermata Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Unilever$57.13B2.34$10.71BN/AN/A

9.7% of Unilever shares are owned by institutional investors. 1.0% of Unilever shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Unilever has a consensus target price of $65.55, suggesting a potential upside of 5.70%. Given Unilever's stronger consensus rating and higher possible upside, analysts plainly believe Unilever is more favorable than Dermata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermata Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Unilever
2 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.33

In the previous week, Unilever had 12 more articles in the media than Dermata Therapeutics. MarketBeat recorded 12 mentions for Unilever and 0 mentions for Dermata Therapeutics. Unilever's average media sentiment score of 0.80 beat Dermata Therapeutics' score of 0.00 indicating that Unilever is being referred to more favorably in the news media.

Company Overall Sentiment
Dermata Therapeutics Neutral
Unilever Positive

Summary

Unilever beats Dermata Therapeutics on 9 of the 9 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRMAW vs. The Competition

Export
MetricDermata TherapeuticsPersonal Care Products IndustryConsumer Staples SectorNASDAQ Exchange
Market CapN/A$22.89B$15.57B$12.85B
Dividend YieldN/A4.52%3.27%11.17%
P/E RatioN/A20.3014.0625.36
Price / SalesN/A12.49262,948.62116.83
Price / CashN/A27.0656.8751.52
Price / BookN/A2.884.766.20
Net IncomeN/A$1.13B$837.55M$358.50M
7 Day PerformanceN/A-1.85%-1.42%-2.35%
1 Month PerformanceN/A-1.57%-1.79%-3.23%
1 Year PerformanceN/A-15.14%10.48%8.79%

Dermata Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRMAW
Dermata Therapeutics
N/A$0.00
flat		N/A-96.3%$0.00N/AN/A8
DSYWW
Big Tree Cloud
N/A$0.02
+1.8%		N/A-55.4%$0.00$2.02MN/A82
PRENW
Prenetics Global
N/A$0.01
flat		N/AN/A$0.00$154.59MN/A1
WALDW
Waldencast
N/A$0.02
-21.1%		N/A-36.6%$0.00$272.07MN/A284
PG
Procter & Gamble
4.2544 of 5 stars		$142.62
-2.0%		$161.19
+13.0%		-8.2%$331.17B$87.03B21.54104,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DRMAW) was last updated on 9/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel